Performance Labs Pte. Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Production of aspirin-triggered resolvins without the use of aspirin in a dietary omega-3 supplement (US 11,707,469) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Apr 1, 2027The maintenance fee for Multivitamin capable of beneficial gene regulation through microRNA (miRNA) (US 10,426,756) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
- 1 fee due Jun 30, 2027The maintenance fee for Device and method of using volatile organic compounds that affect mood, emotion or a physiologic state (US 10,517,879) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for Production of aspirin-triggered resolvins without the use of aspirin in a dietary omega-3 supplement (US 10,624,907) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,517,879 | Device and method of using volatile organic compounds that affect mood, emotion or a physiologic state In force · From the USPTO record | In force | From the USPTO record | |
| US 10,426,756 | Multivitamin capable of beneficial gene regulation through microRNA (miRNA) In force · From the USPTO record | In force | From the USPTO record | |
| US 10,857,124 | Multivitamin capable of beneficial gene regulation through microRNA (MIRNA) In force · From the USPTO record | In force | From the USPTO record | |
| US 10,624,907 | Production of aspirin-triggered resolvins without the use of aspirin in a dietary omega-3 supplement In force · From the USPTO record | In force | From the USPTO record | |
| US 11,484,547 | Compositions and methods for cholesterol, glucose and microbiome control In force · From the USPTO record | In force | From the USPTO record | |
| US 11,707,469 | Production of aspirin-triggered resolvins without the use of aspirin in a dietary omega-3 supplement In force · From the USPTO record | In force | From the USPTO record | |
| US 12,773,439 | Botanical Extraction In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 4 no status recorded